Adjunct Assistant Professor
Johns Hopkins University
St. Petersburg, Florida, United States
Pharmaceutical executive with over 30 years in pharmaceutical development, including pediatric products. Daniel retired from Janssen R&D LLC (Johnson & Johnson) as Sr. Scientific Director, where he co-chaired the internal Pediatric Formulation Network. At J&J, he led the pharmaceutical development of several pediatric products, e.g., the new chewable tablet of mebendazole for donation. Daniel holds a degree in pharmacy (ETH Zurich) and a doctorate from the University of Lausanne. He is a member of the Pediatric Working Group of the International Consortium (IQ) for Quality in Pharmaceutical Development and a formulation expert for the pan-European "Conect4Children" initiative. Daniel is a founding member of the society of “Paediatric Medicines and Health Initiative”, India. In 2020, he joined Johns Hopkins University, School of Medicine, All Children’s Hospital in St. Petersburg, FL as adjunct assistant Professor.
Disclosure information not submitted.
Workshop: Pediatric Modified Release -What’s the Problem and What are Some Solutions?
Monday, July 8, 2024
1:00 PM – 5:00 PM CET
